MARKET

CODX

CODX

Co-Diagnostics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.30
-0.32
-2.35%
Closed 19:22 10/20 EDT
OPEN
13.64
PREV CLOSE
13.62
HIGH
13.73
LOW
13.01
VOLUME
815.82K
TURNOVER
--
52 WEEK HIGH
30.99
52 WEEK LOW
0.8463
MARKET CAP
373.50M
P/E (TTM)
73.32
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Co-Diagnostics: Diversified In COVID-19 Diagnostics
"The misfortune of some makes the happiness of others" goes an old saying.In this case, high COVID-19 infection rates have been a boon for companies like Co-Diagnostics and their investors.Further rise in infection rates may just be the trigger needed to boost the stock price but beware, as there are others in the same business too.Moreover, despite a lawsuit filed against CODX, the company's Logix testing kit is still present in the FDA's list.Given the high percentage of a short position, it would be better to be on the sidelines and wait for an update concerning the lawsuit.
Seekingalpha · 15h ago
We Like Co-Diagnostics' (NASDAQ:CODX) Returns And Here's How They're Trending
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Simply Wall St. · 3d ago
American Bio Medica inks distribution pact with Co-Diagnostics's COVID-19 test
American Bio Medica ([[ABMC]] +11.2%) has signed a distribution agreement with Co-Diagnostics ([[CODX]] +1.7%) that provides ABMC the right to market and sell latter's Logix Smart COVID-19 tests in the U.S.
Seekingalpha · 10/07 17:23
Implied Volatility Surging for Co-Diagnostics (CODX) Stock Options
Zacks · 10/07 13:39
Company News for Oct 5, 2020
Companies in the news are: UBER, WMT, BBBY, CODX
Zacks · 10/05 14:18
P/E Ratio Insights for Co-Diagnostics
In the current session, Co-Diagnostics Inc. (NASDAQ: CODX) is trading at $13.46, after a 3.78% gain. Over the past month, the stock increased by 63.25%, and in the past year, by 1134.10%. With performance like this, long-term shareholders optimistic but others are more likely to look into the price-to-earnings
Benzinga · 10/02 14:55
Co-Diagnostics COVID-19 molecular test gets U.S. nod for use with saline oral rinse
Co-Diagnostics (CODX) announces that customer Access Genetics, LLC, doing business as OralDNA Labs, has received an amended emergency use authorization from the FDA allowing testing with CODX's Logix Smart COVID-19
Seekingalpha · 10/02 11:12
Co-Diagnostics's Logix Smart kit to be used with newly FDA authorized saline oral rinse COVID-19 test
The FDA has approved amended emergency use authorization of a COVID-19 test kit developed at Access Genetics (dba OralDNA Labs), that allows testing from simple saline 30 second swish and
Seekingalpha · 10/02 10:48
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CODX. Analyze the recent business situations of Co-Diagnostics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CODX stock price target is 35.33 with a high estimate of 43.00 and a low estimate of 30.00.
EPS
Institutional Holdings
Institutions: 98
Institutional Holdings: 7.07M
% Owned: 25.18%
Shares Outstanding: 28.08M
TypeInstitutionsShares
Increased
19
1.72M
New
59
3.07M
Decreased
11
285.00K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.48%
Healthcare Equipment & Supplies
-0.72%
Key Executives
Chairman/President/Chief Executive Officer/Director
Dwight Egan
Chief Financial Officer/Secretary
Reed Benson
Chief Technology Officer
Brent Satterfield
Independent Director
Eugene Durenard
Independent Director
Edward Murphy
Independent Director
James Nelson
Independent Director
Richard Serbin
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CODX
Co-Diagnostics, Inc. is a molecular diagnostics company. The Company is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. It also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The Company uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Co-Diagnostics Inc stock information, including NASDAQ:CODX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CODX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CODX stock methods without spending real money on the virtual paper trading platform.